Not Yet RecruitingPhase 2

SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy

China33 participantsStarted 2026-03-15

Plain-language summary

This study is a single-arm, exploratory clinical trial aimed at evaluating the efficacy and safety of SHR-1701 in combination with liposomal irinotecan (II) in patients with esophageal squamous cell carcinoma who have received prior immunotherapy. Eligible patients with esophageal cancer will be treated with SHR-1701 in combination with liposomal irinotecan (II).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signed written informed consent, voluntarily participating in this study;
✓. Histopathologically or cytologically confirmed esophageal squamous cell carcinoma;
✓. Prior treatment with immunotherapy;
✓. At least one measurable lesion as assessed by RECIST version 1.1;
✓. Age ≥ 18 years, male or female;
✓. ECOG performance status of 0 or 1;
✓. Life expectancy \> 3 months;
✓. Adequate organ function:

Exclusion criteria

✕. Use of immunosuppressive medications or systemic corticosteroid therapy for immunosuppressive purposes (dose \> 10 mg/day prednisone or equivalent) within 2 weeks prior to the first dose of study drug; inhaled or topical steroids and adrenal corticosteroid replacement at doses \> 10 mg/day prednisone or equivalent are permitted in the absence of active autoimmune disease.
✕. Receipt of a live attenuated vaccine within 4 weeks prior to the first dose of study drug.
✕. Major surgery or significant traumatic injury within 4 weeks prior to the first dose of study drug.

What they're measuring

Objective Response Rate

Timeframe: through study completion, an average of 12 weeks

Trial details

NCT IDNCT07524374

SponsorZhigang Li

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-09-30

Contact for this trial

Haoran Zhai

021-34206890 haoran.zhai.123@hotmail.com

View on ClinicalTrials.gov More ESCC trials